“We [at GenesisCare] would be really interested in looking at strategies to identify men that we think are aggressive but localized and offer them a chance to do a shorter course hormonal therapy, which is going to substantially improve quality of life without losing on the efficacy end,” says Bridget F. Koontz, MD.
In this video, Bridget F. Koontz, MD, discusses the background, findings, and takeaways of the study, “Five year results of short course complete androgen blockade with abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high risk prostate cancer,” presented recently at the 2021 American Society for Radiation Oncology Annual Meeting. She also reports updates in GenesisCare technologies related to prostate cancer. Koontz is a radiation oncologist, US chief medical officer, and deputy global chief medical officer for GenesisCare.
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.